KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Long-Term Debt Repayments (2016 - 2025)

Abbott Laboratories' Long-Term Debt Repayments history spans 14 years, with the latest figure at $501.0 million for Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments rose 24950.0% year-over-year to $501.0 million; the TTM value through Sep 2025 reached $1.5 billion, up 2.73%, while the annual FY2021 figure was $48.0 million, 96.4% down from the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $501.0 million at Abbott Laboratories, up from $1.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.4 billion in Q3 2023 and bottomed at $1.0 million in Q2 2022.
  • The 5-year median for Long-Term Debt Repayments is $3.0 million (2021), against an average of $269.4 million.
  • The largest annual shift saw Long-Term Debt Repayments surged 144400.0% in 2023 before it tumbled 99.86% in 2024.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $3.0 million in 2021, then crashed by 66.67% to $1.0 million in 2022, then soared by 144400.0% to $1.4 billion in 2023, then crashed by 99.86% to $2.0 million in 2024, then surged by 24950.0% to $501.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Long-Term Debt Repayments are $501.0 million (Q3 2025), $1.0 million (Q2 2025), and $1.0 billion (Q1 2025).